O	0	10	Evaluation
O	11	13	of
B-intervention	14	26	lecithinized
I-intervention	27	32	human
I-intervention	33	44	recombinant
I-intervention	45	50	super
I-intervention	51	56	oxide
I-intervention	57	66	dismutase
O	67	69	as
O	70	86	cardioprotectant
O	87	89	in
O	90	103	anthracycline
O	103	104	-
O	104	111	treated
O	112	118	breast
O	119	125	cancer
O	126	134	patients
O	134	135	.

O	136	149	Anthracycline
O	149	150	-
O	150	157	induced
O	158	172	cardiotoxicity
O	173	175	is
O	176	177	(
O	177	183	partly
O	183	184	)
O	185	193	mediated
O	194	196	by
O	197	201	free
O	202	209	radical
O	210	218	overload
O	218	219	.

O	220	221	A
O	222	232	randomized
O	233	238	study
O	239	242	was
O	243	252	performed
O	253	255	in
O	256	262	breast
O	263	269	cancer
O	270	278	patients
O	279	281	to
O	282	293	investigate
O	294	301	whether
O	302	306	free
O	307	314	radical
O	315	324	scavenger
O	325	330	super
O	331	336	oxide
O	337	346	dismutase
O	347	348	(
O	348	351	SOD
O	351	352	)
O	353	361	protects
O	362	369	against
B-condition	370	383	anthracycline
I-condition	383	384	-
I-condition	384	391	induced
I-condition	392	406	cardiotoxicity
O	407	409	as
O	410	418	measured
O	419	421	by
O	422	429	changes
O	430	432	in
O	433	437	echo
O	437	438	,
O	439	458	electrocardiography
O	459	462	and
O	463	465	an
O	466	471	array
O	472	474	of
O	475	485	biomarkers
O	485	486	.

B-total-participants	487	493	Eighty
B-eligibility	494	500	female
I-eligibility	500	501	,
I-eligibility	502	514	chemotherapy
I-eligibility	514	515	-
I-eligibility	515	517	na
I-eligibility	517	518	Ã¯
I-eligibility	518	520	ve
I-eligibility	521	527	breast
I-eligibility	528	534	cancer
I-eligibility	535	543	patients
O	544	545	(
O	545	551	median
O	552	555	age
O	556	558	49
O	558	559	,
O	560	565	range
B-age	566	568	24
I-age	568	569	-
I-age	569	571	67
I-age	572	577	years
O	577	578	)
O	579	588	scheduled
O	589	592	for
O	593	597	four
O	598	600	or
O	601	605	five
O	606	613	courses
O	614	616	of
O	617	625	adjuvant
O	626	627	3
O	628	634	weekly
O	635	646	doxorubicin
O	647	651	plus
O	652	668	cyclophosphamide
O	669	670	(
O	670	672	AC
O	672	673	)
O	674	686	chemotherapy
O	686	687	,
O	688	692	were
O	693	701	randomly
O	702	710	assigned
O	711	713	to
O	714	721	receive
O	722	724	80
O	725	727	mg
O	728	730	PC
O	730	731	-
O	731	734	SOD
O	735	736	(
O	736	741	human
O	742	753	recombinant
O	754	757	SOD
O	758	763	bound
O	764	766	to
O	767	775	lecithin
O	775	776	)
O	777	779	or
B-control	780	787	placebo
O	787	788	,
O	789	801	administered
O	802	815	intravenously
O	816	817	(
O	817	818	i
O	818	819	.
O	819	820	v
O	820	821	.
O	821	822	)
O	823	834	immediately
O	835	840	prior
O	841	843	to
O	844	848	each
O	849	851	AC
O	852	858	course
O	858	859	.

O	860	863	The
O	864	871	primary
O	872	875	end
O	876	881	point
O	882	885	was
B-outcome-Measure	886	896	protection
I-outcome-Measure	897	904	against
I-outcome-Measure	905	912	cardiac
I-outcome-Measure	913	919	damage
O	920	929	evaluated
O	930	935	using
O	936	952	echocardiography
O	952	953	,
O	954	956	QT
O	957	968	assessments
O	969	972	and
O	973	974	a
O	975	978	set
O	979	981	of
O	982	993	biochemical
O	994	1001	markers
O	1002	1005	for
O	1006	1016	myocardial
O	1017	1025	function
O	1025	1026	,
O	1027	1036	oxidative
O	1037	1043	stress
O	1044	1047	and
O	1048	1060	inflammation
O	1060	1061	.

O	1062	1073	Assessments
O	1074	1078	were
O	1079	1088	performed
O	1089	1095	before
O	1096	1099	and
O	1100	1106	during
O	1107	1111	each
O	1112	1118	course
O	1119	1121	of
O	1122	1134	chemotherapy
O	1134	1135	,
O	1136	1139	and
O	1140	1142	at
O	1143	1144	1
O	1144	1145	,
O	1146	1147	4
O	1148	1151	and
O	1152	1153	9
O	1154	1160	months
O	1161	1166	after
O	1167	1177	completion
O	1178	1180	of
O	1181	1184	the
O	1185	1197	chemotherapy
O	1198	1205	regimen
O	1205	1206	.

O	1207	1209	In
O	1210	1213	all
O	1214	1222	patients
O	1223	1230	cardiac
O	1231	1238	effects
O	1239	1243	such
O	1244	1246	as
O	1247	1256	increases
O	1257	1259	in
B-outcome	1260	1262	NT
I-outcome	1262	1263	-
I-outcome	1263	1269	proBNP
I-outcome	1270	1283	concentration
I-outcome	1284	1287	and
I-outcome	1288	1300	prolongation
I-outcome	1301	1303	of
I-outcome	1304	1307	the
I-outcome	1308	1311	QTc
I-outcome	1312	1320	interval
O	1321	1325	were
O	1326	1333	noticed
O	1333	1334	.

O	1335	1340	There
O	1341	1345	were
O	1346	1348	no
O	1349	1360	differences
O	1361	1368	between
O	1369	1372	the
O	1373	1375	PC
O	1375	1376	-
O	1376	1379	SOD
O	1380	1383	and
O	1384	1391	placebo
O	1391	1392	-
O	1392	1399	treated
O	1400	1408	patients
O	1409	1411	in
B-outcome	1412	1420	systolic
I-outcome	1421	1423	or
I-outcome	1424	1433	diastolic
I-outcome	1434	1441	cardiac
I-outcome	1442	1450	function
O	1451	1453	or
O	1454	1457	for
O	1458	1461	any
O	1462	1467	other
O	1468	1470	of
O	1471	1474	the
O	1475	1485	biomarkers
O	1486	1490	used
O	1491	1493	to
O	1494	1500	assess
O	1501	1504	the
O	1505	1512	cardiac
O	1513	1520	effects
O	1521	1523	of
O	1524	1538	anthracyclines
O	1538	1539	.

O	1540	1542	PC
O	1542	1543	-
O	1543	1546	SOD
O	1547	1549	at
O	1550	1551	a
O	1552	1556	dose
O	1557	1559	of
O	1560	1562	80
O	1563	1565	mg
O	1566	1567	i
O	1567	1568	.
O	1568	1569	v
O	1569	1570	.
O	1571	1573	is
O	1574	1577	not
O	1578	1594	cardioprotective
O	1595	1597	in
O	1598	1606	patients
O	1607	1611	with
O	1612	1618	breast
O	1619	1628	carcinoma
O	1629	1636	treated
O	1637	1641	with
O	1642	1656	anthracyclines
O	1656	1657	.
